Compare IMCR & WLFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMCR | WLFC |
|---|---|---|
| Founded | 2008 | 1985 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2016 | 1997 |
| Metric | IMCR | WLFC |
|---|---|---|
| Price | $30.88 | $223.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 1 |
| Target Price | $66.33 | ★ $160.00 |
| AVG Volume (30 Days) | ★ 556.7K | 109.6K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.86% |
| EPS Growth | 30.39 | ★ 146.23 |
| EPS | 0.25 | ★ 3.26 |
| Revenue | $249,428,000.00 | ★ $569,223,000.00 |
| Revenue This Year | $14.57 | $2.75 |
| Revenue Next Year | $8.21 | $7.35 |
| P/E Ratio | $122.16 | ★ $68.26 |
| Revenue Growth | ★ 43.05 | 36.00 |
| 52 Week Low | $27.56 | $114.01 |
| 52 Week High | $40.71 | $239.44 |
| Indicator | IMCR | WLFC |
|---|---|---|
| Relative Strength Index (RSI) | 61.86 | 73.67 |
| Support Level | $27.66 | $165.65 |
| Resistance Level | $31.56 | $239.44 |
| Average True Range (ATR) | 1.12 | 9.35 |
| MACD | 0.28 | 4.46 |
| Stochastic Oscillator | 73.84 | 91.23 |
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum Lease rent revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.